Abstract
Background. The study highlights the anti-inflammatory and anti-exudative effects of preparations derived from Aesculus hippocastanum L., specifically Escuzan® and Betta-Escin, in treating vascular inflammation in the lower extremities and preventing atherosclerosis. These properties make them promising agents for managing conditions involving vascular damage and inflammation.
Materials. The preparations evaluated were Escuzan® and Betta-Escin. The anti-inflammatory efficacy of these agents was studied in a long-term compression syndrome (DFS) model. The proliferative phase of inflammation was assessed using the Cotton pellet method, with granulation tissue weight in the control group set at 50.4 g ± 0.5 mg (100%) as a baseline.
Results. Betta-Escin demonstrated significant anti-exudative activity, reducing exudation by 32.1%, 38.4%, and 42.1% at doses of 10, 30, and 50 mg/kg, respectively. Comparatively, Escuzan® reduced exudation by 30.2%. In the proliferative phase of inflammation, Betta-Escin reduced inflammatory cell proliferation by 22.3%, 27.2%, and 31.2%, whereas Escuzan® achieved a reduction of 20.8%. Betta-Escin exhibited statistically superior efficacy (P<0.05) in reducing both exudation and inflammatory cell proliferation compared to Escuzan®.
Conclusion. Betta-Escin showed greater efficacy than Escuzan® in reducing exudation and inflammatory cell proliferation in an experimental DFS model. These findings suggest that Betta-Escin is a more effective therapeutic option for managing vascular inflammation and promoting recovery in conditions such as long-term compression syndrome.